DVAX

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: JNJ PFE MRNA GILD BNTX AZN-D REGN NVAX VIR VXRT

| Held by: VTI VXF VTWO VIOO VHT VIOV VTWG VTHR CSA CSF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.38	Insider Own	0.18%	Shs Outstand	117.36M	Perf Week	-
Market Cap	1.82B	Forward P/E	-	EPS next Y	-	Insider Trans	-91.25%	Shs Float	117.22M	Perf Month	-0.77%
Enterprise Value	1.46B	PEG	-	EPS next Q	-	Inst Own	99.70%	Short Float	8.35%	Perf Quarter	38.89%
Income	-43.40M	P/S	5.51	EPS this Y	-	Inst Trans	-	Short Ratio	3.12	Perf Half Y	43.65%
Sales	330.51M	P/B	3.41	EPS next Y	-	ROA	-4.32%	Short Interest	9.79M	Perf YTD	0.78%
Book/sh	4.55	P/C	2.81	EPS next 5Y	-	ROE	-7.14%	52W High	15.73 -1.46%	Perf Year	17.87%
Cash/sh	5.52	P/FCF	22.60	EPS past 3/5Y	-27.72% -	ROIC	-5.57%	52W Low	9.20 68.48%	Perf 3Y	40.91%
Dividend Est.	-	EV/EBITDA	78.23	Sales past 3/5Y	-14.08% 51.08%	Gross Margin	83.17%	Volatility	0.23% 0.40%	Perf 5Y	46.23%
Dividend TTM	-	EV/Sales	4.42	EPS Y/Y TTM	-310.39%	Oper. Margin	3.16%	ATR (14)	0.11	Perf 10Y	-14.88%
Dividend Ex-Date	-	Quick Ratio	6.94	Sales Y/Y TTM	26.73%	Profit Margin	-13.13%	RSI (14)	76.00	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.62	EPS Q/Q	81.60%	SMA20	-0.38%	Beta	0.93	Target Price	16.00
Payout	0.00%	Debt/Eq	0.54	Sales Q/Q	17.67%	SMA50	12.55%	Rel Volume	0.00	Prev Close	15.50
Employees	405	LT Debt/Eq	0.46	Earnings	Nov 05 AMC	SMA200	38.23%	Avg Volume	3.14M	Price	15.50
IPO	Feb 19, 2004	Option/Short	Yes / No	EPS/Sales Surpr.	66.53% 0.93%	Trades		Volume	7,106,122	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-11-25	Downgrade	Goldman	Neutral → Sell	$15 → $12
Feb-01-24	Initiated	Goldman	Neutral	$20
Sep-27-22	Initiated	JMP Securities	Mkt Outperform	$22
Jan-06-22	Resumed	Goldman	Buy	$38
Aug-06-21	Initiated	Goldman	Buy	$19
Aug-07-20	Reiterated	H.C. Wainwright	Buy	$14 → $12
Aug-03-20	Reiterated	H.C. Wainwright	Buy	$12 → $14
Jun-15-20	Initiated	Evercore ISI	Outperform	$14
Oct-18-19	Initiated	H.C. Wainwright	Buy	$13
Jul-11-19	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$20
Feb-27-19	Reiterated	Cantor Fitzgerald	Overweight	$32 → $28
May-10-18	Upgrade	JP Morgan	Neutral → Overweight
Mar-08-18	Reiterated	Cantor Fitzgerald	Overweight	$25 → $27
Feb-14-18	Downgrade	JP Morgan	Overweight → Neutral
Sep-25-17	Reiterated	RBC Capital Mkts	Outperform	$26 → $28
Sep-15-17	Initiated	Cantor Fitzgerald	Overweight	$24
Jul-31-17	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$7 → $26
Jul-31-17	Upgrade	JP Morgan	Neutral → Overweight
May-09-17	Reiterated	RBC Capital Mkts	Sector Perform	$6 → $7
Apr-28-16	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$48 → $17

Show Previous Ratings

Feb-04-26 06:15PM	Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600 (PR Newswire)
Jan-29-26 11:21AM	Sanofi Beats on Q4 Earnings, Expects Profitable Growth in 2026 (Zacks)
Jan-14-26 10:57AM	Jim Cramer Highlights Sanofi's Bid for Dynavax (Insider Monkey)
Jan-06-26 10:50AM	Halper Sadeh LLC Encourages DBRG, FOLD, DVAX Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Dec-30-25 10:20AM	Halper Sadeh LLC Encourages DVAX, CWAN, DBRG Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
05:28AM	Loading…
Dec-29-25 05:28AM	Sanofi Agrees to Buy Dynavax for $2.2 Billion After FDA MS Drug Rejection (GuruFocus.com)
Dec-26-25 02:56PM	Christmas Week Brings S&P 500 Records, Tech Volatility (Schaeffer's Research)
06:07AM	S&P Futures Muted in Thin Post-Christmas Trade (Barchart)
03:08AM	Company News for Dec 26, 2025 (Zacks)
Dec-25-25 10:40AM	Dynavax (DVAX) Rockets 38% on Sanofi $2-Billion Merger (Insider Monkey)
12:47AM	Asian shares are mixed after US stocks drift to more records (Associated Press Finance)
Dec-24-25 03:55PM	Why Dynavax Stock Soared Today (Motley Fool) +38.19%
02:23PM	Stocks End Mildly Higher as Bullish Sentiment Continues (Barchart)
01:24PM	How major US stock indexes fared Wednesday, 12/24/2025 (Associated Press)
01:04PM	Sanofi To Buy Vaccine Maker Dynavax For $2.2 Billion (Investor's Business Daily)
12:08PM	Loading…
12:08PM	This Biotech Stock Soars 39%. Sanofi Is Buying It for $2.2 Billion. (Barrons.com)
11:55AM	Dynavax Technologies Stock Soars on Buyout Buzz (Schaeffer's Research)
11:24AM	Sanofi to Acquire Dynavax for $2.2 Billion, Expanding Vaccine Portfolio (GuruFocus.com)
11:07AM	Stock Market Today: Dow Rises As Nike Jumps On Apple CEO Stake (Live Coverage) (Investor's Business Daily)
11:07AM	Soft Weekly Jobless Claims Data (Zacks)
10:49AM	Shares of Dynamax Are Up Nearly 40% Today. Here's Why The Stock Is Flying (Investopedia)
10:35AM	Xmas Eve Jobless Claims: Still Accommodating (Zacks)
09:59AM	Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise (Zacks)
09:36AM	KB Home downgraded, Costco upgraded: Wall Street's top analyst calls (The Fly)
09:36AM	KB Home downgrade, Costco upgraded: Wall Street's top analyst calls (The Fly)
09:24AM	BP to sell 65% of Castrol stake, Sanofi's $2.2B deal for Dynavax (Yahoo Finance Video)
07:59AM	This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion. (Barrons.com)
07:43AM	Biggest Mover Wednesday: Dynavax Stock Soars on $2.2 billion Acquisition Deal (GuruFocus.com)
07:09AM	Nike, UiPath gain in premarket; Intel falls (Investing.com)
07:04AM	U.S stocks on the move in Wednesday morning pre-market trading (MarketWatch)
06:34AM	Loading…
06:34AM	Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal (The Wall Street Journal)
04:57AM	Stock Market Today: Dow, S&P 500 and Nasdaq point to lower start ahead of shortened holiday trading session with U.S. jobless claims due later. Gold, silver and copper near record highs. (MarketWatch)
01:23AM	Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline (PR Newswire)
Dec-01-25 04:41PM	Moderna Slammed By 'Fear, Confusion' After FDA Alleges Covid Shots Killed 10 (Investor's Business Daily) -5.80%
12:35PM	Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men (MarketWatch)
10:09AM	Moderna, BioNTech Slammed After FDA Links Covid Shots To 10 Deaths (Investor's Business Daily)
Nov-19-25 04:01PM	Dynavax to Participate at the 8th Annual Evercore Healthcare Conference (PR Newswire)
Nov-06-25 12:01AM	Dynavax Technologies Corp (DVAX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) +6.70%
Nov-05-25 05:20PM	Dynavax Technologies (DVAX) Surpasses Q3 Earnings Estimates (Zacks)
04:18PM	Dynavax Technologies: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program (PR Newswire)
04:00PM	Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program (PR Newswire)
Nov-04-25 04:15PM	Qiagen (QGEN) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Nov-03-25 05:55PM	Nuvation Bio Inc. (NUVB) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Oct-22-25 04:01PM	Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025 (PR Newswire)
Oct-21-25 04:01PM	Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial (PR Newswire)
Sep-22-25 10:22AM	Amgen (AMGN) Moves 3.5% Higher: Will This Strength Last? (Zacks)
Sep-02-25 04:05AM	Dynavax Technologies Corporation (DVAX) Reports Record $92M HEPLISAV-B Revenue, Raises 2025 Outlook (Insider Monkey)
Aug-27-25 04:05PM	Dynavax to Participate in the 2025 Wells Fargo Healthcare Conference (PR Newswire)
Aug-22-25 07:25AM	Dynavaxs shingles vaccine shows promise in trial against GSKs Shingrix (Clinical Trials Arena)
Aug-21-25 08:00AM	Dynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-in-Class Shingles Vaccine Profile (PR Newswire) +5.09%
Aug-07-25 05:10PM	Dynavax Technologies (DVAX) Q2 Earnings and Revenues Beat Estimates (Zacks) -6.60%
04:11PM	Dynavax Technologies: Q2 Earnings Snapshot (Associated Press Finance)
04:00PM	Dynavax Reports Second Quarter 2025 Financial Results (PR Newswire)
Aug-06-25 05:25PM	Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Jul-29-25 04:02PM	Dynavax to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025 (PR Newswire)
Jul-28-25 05:20PM	Exelixis (EXEL) Beats Q2 Earnings Estimates (Zacks)
Jul-06-25 04:15AM	Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31 (Insider Monkey)
Jun-11-25 11:01AM	Dynavax Stockholders Elect All Dynavax Director Nominees at 2025 Annual Meeting (PR Newswire)
Jun-09-25 08:30AM	Deep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the Boardroom (Business Wire)
07:30AM	Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting (PR Newswire)
Jun-04-25 04:59PM	Dynavax Comments on Glass Lewis Recommendation (PR Newswire)
09:27AM	Glass Lewis Recommends Shareholders Support Deep Track's Case for Board Change at Dynavax Technologies (Business Wire)
May-28-25 04:10PM	Dynavax to Present at William Blair's 45th Annual Growth Stock Conference (PR Newswire)
May-23-25 06:12PM	Deep Track Capital Comments on ISS Recommendation (Business Wire)
01:44PM	Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Four of Dynavax's Highly Qualified Director Nominees (PR Newswire)
May-15-25 04:00PM	Deep Track Capital Issues Letter to Fellow Dynavax Technologies Shareholders Detailing Critical Issues in Advance of Annual Meeting (Business Wire)
May-12-25 07:30AM	Dynavax Files Investor Presentation Highlighting Superior Strategy and Board That is Delivering Strong Financial Results and Significant Long-Term Value (PR Newswire)
May-09-25 08:38PM	/C O R R E C T I O N -- Dynavax Technologies/ (PR Newswire)
May-08-25 12:00PM	Dynavax Technologies (DVAX) Upgraded to Buy: Here's Why (Zacks)
May-07-25 04:45PM	Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum (PR Newswire) -10.99%
03:19AM	Dynavax Technologies Corp (DVAX) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com)
May-06-25 05:15PM	Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs (PR Newswire)
08:00AM	Deep Track Capital Releases Investor Presentation on Dynavax Technologies (Business Wire)
May-05-25 08:10AM	TG Therapeutics (TGTX) Lags Q1 Earnings Estimates (Zacks)
May-01-25 08:00AM	Dynavax Announces Nationwide Harris Poll Survey Results Finding Americans Underestimate the Serious Consequences of Hepatitis B and Vaccine Protection Benefits (PR Newswire)
Apr-29-25 07:30AM	Dynavax Highlights Superior Board Leadership Overseeing Long-Term Value Creation Strategy (PR Newswire)
Apr-22-25 04:00PM	Dynavax to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025 (PR Newswire)
Apr-21-25 04:05PM	Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders (Business Wire)
Apr-17-25 09:17AM	GSK's Pentavalent Meningococcal Jab Recommended for Use by ACIP (Zacks)
07:15AM	Dynavax Files Definitive Proxy Statement and Sends Letter to Stockholders (PR Newswire)
Apr-16-25 09:48AM	MURA Soars as it Explores Strategic Options Post Cancer Study Failures (Zacks) -6.66%
08:52AM	DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up (Zacks)
08:00AM	Deep Track Capital Comments on Dynavax Technologies Rejection of Most Recent Settlement Offer (Business Wire)
Apr-15-25 10:20AM	Buy The Dips, Sell The Rips (Seeking Alpha)
Apr-11-25 11:57AM	KROS Initiates Exploring Strategic Alternatives, Stock Gains 18.5% (Zacks)
Apr-10-25 10:53AM	PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose (Zacks) -8.81%
09:58AM	ANIX Gets New Patent for Breast Cancer Vaccine Technology, Stock Up (Zacks)
Apr-09-25 12:57PM	3 Biotech Stocks Holding Their Own (Seeking Alpha)
10:01AM	RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study (Zacks)
Apr-08-25 12:18PM	AtriCure Drops 25%: Bargain Or Caution Sign? (Seeking Alpha) -5.92%
11:29AM	PCRX Stock Soars on Exparel Patent Settlement With Generic Players (Zacks)
11:21AM	RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study (Zacks)
Apr-07-25 10:53AM	AZN Gets EU Nod for Expanded Use of Two Separate Cancer Drugs (Zacks)
Apr-04-25 01:45PM	Bayer's Vividion Initiates Dosing in Early-Stage Cancer Study (Zacks)
01:10PM	AMGN's Uplizna Gets FDA Nod for 2nd Rare Autoimmune Disease Indication (Zacks)
09:37AM	PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study (Zacks)
Apr-03-25 05:40PM	Dynavax Files Preliminary Proxy Statement (PR Newswire)
11:27AM	SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases (Zacks)

Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018TM adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Novack David F	President & COO	Jan 15 '26	Option Exercise	9.83	114,000	1,120,280	177,344	Jan 20 04:33 PM
Novack David F	President & COO	Jan 15 '26	Sale	15.64	114,000	1,782,960	63,344	Jan 20 04:33 PM
DAVID NOVACK	Officer	Jan 15 '26	Proposed Sale	15.64	114,000	1,782,727		Jan 15 04:11 PM
Novack David F	President & COO	Dec 24 '25	Option Exercise	8.03	30,000	240,800	141,451	Dec 29 04:09 PM
Novack David F	President & COO	Dec 24 '25	Sale	15.49	30,000	464,700	111,451	Dec 29 04:09 PM
DAVID NOVACK	Officer	Dec 24 '25	Proposed Sale	15.49	30,000	464,700		Dec 29 09:37 AM
Myers Scott Dunseth	Director	Aug 22 '25	Buy	10.82	3,800	41,116	35,004	Aug 25 08:50 AM
Deep Track Biotechnology Maste	10% Owner	Aug 21 '25	Sale	11.03	1,094,994	12,077,784	16,696,492	Aug 22 08:49 PM
Deep Track Biotechnology Maste	10% Owner	Aug 22 '25	Sale	10.59	970,143	10,273,814	15,726,349	Aug 22 08:49 PM
Novack David F	President & COO	Mar 24 '25	Option Exercise	6.80	10,000	68,050	18,078	Mar 26 05:04 PM
Novack David F	President & COO	Mar 24 '25	Sale	14.00	10,000	140,000	8,078	Mar 26 05:04 PM
DAVID NOVACK	Officer	Mar 24 '25	Proposed Sale	14.00	10,000	140,000		Mar 24 04:23 PM
Novack David F	President & COO	Mar 18 '25	Sale	13.58	14,020	190,392	8,078	Mar 20 06:15 PM
DAVID NOVACK	Officer	Mar 18 '25	Proposed Sale	13.58	14,020	190,386		Mar 18 04:17 PM
Novack David F	President & COO	Mar 07 '25	Sale	14.39	32,764	471,474	22,098	Mar 10 09:44 PM
DAVID NOVACK	Officer	Mar 07 '25	Proposed Sale	14.39	32,764	471,376		Mar 07 05:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Dynavax Technologies Corp

Upgrade your FINVIZ experience